Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2025 · 68 positions · Total reported value $1.09B · Top-10 concentration 55.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2025 13F filing, Eversept Partners, LP disclosed 68 equity positions with a combined reported value of $1.09B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were NTRA ($134.54M), QQQ ($94.99M), GSK ($86.11M). By sector, the heaviest allocations are Health Care 75.3%, Industrials 10.5%. Versus the prior quarter, allocation shifted toward Industrials (+4.7pp), Other (+3.5pp) and away from Consumer Discretionary (-1.9pp), Health Care (-6.3pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q2 2025 were UNH ($18.95M), ILMN ($18.95M), IQV ($15.38M).

Of the 27 positions fully exited versus the prior quarter, the largest were SPY ($43.02M), NBIX ($18.50M), ALGN ($7.83M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • UNH UNITEDHEALTH GROUP INC · $18.95M
  • ILMN ILLUMINA INC · $18.95M
  • IQV IQVIA HLDGS INC · $15.38M
  • DVAX DYNAVAX TECHNOLOGIES CORP · $11.88M
  • MIRM MIRUM PHARMACEUTICALS INC · $11.82M
  • EOLS EVOLUS INC · $10.78M
  • GERN GERON CORP · $10.32M
  • REGN REGENERON PHARMACEUTICALS · $6.96M

Fully Exited (vs previous quarter)

  • SPY STATE STR SPDR S&P 500 ETF T · prev qtr: $43.02M
  • NBIX NEUROCRINE BIOSCIENCES INC · prev qtr: $18.50M
  • ALGN ALIGN TECHNOLOGY INC · prev qtr: $7.83M
  • TFX TELEFLEX INCORPORATED · prev qtr: $7.83M
  • NVAX NOVAVAX INC · prev qtr: $2.34M
  • XOMA XOMA ROYALTY CORPORATION · prev qtr: $897.19K

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 75.3%
Industrials 10.5%
Financials 0.1%
Other 12.6%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 796.38K $134.54M 12.38%
12.38%
Reduce
2 172.20K $94.99M 8.74%
8.74%
Add
3 2.24M $86.11M 7.92%
7.92%
Reduce
4 2.38M $56.14M 5.16%
5.16%
Add
5 510.33K $49.36M 4.54%
4.54%
Add
6 1.30M $42.21M 3.88%
3.88%
Add
7 99.98K $38.30M 3.52%
3.52%
Reduce
8 4.07M $38.07M 3.50%
3.50%
Reduce
9 839.28K $34.58M 3.18%
3.18%
Add
10 1.90M $26.60M 2.45%
2.45%
Add
11 588.90K $23.27M 2.14%
2.14%
Add
12 398.73K $21.64M 1.99%
1.99%
Add
13 164.47K $21.34M 1.96%
1.96%
Reduce
14 6.14M $20.89M 1.92%
1.92%
Reduce
15 1.53M $20.54M 1.89%
1.89%
Add
16 394.14K $20.28M 1.86%
1.86%
Add
17 1.32M $19.46M 1.79%
1.79%
Add
18 2.08M $19.44M 1.79%
1.79%
Hold
19 60.74K $18.95M 1.74%
1.74%
New
20 198.58K $18.95M 1.74%
1.74%
New
21 1.05M $17.65M 1.62%
1.62%
Reduce
22 838.74K $17.07M 1.57%
1.57%
Add
23 59.37K $17.06M 1.57%
1.57%
Add
24 155.87K $16.33M 1.50%
1.50%
Reduce
25 97.60K $15.38M 1.42%
1.42%
New
26 277.32K $15.33M 1.41%
1.41%
Reduce
27 1.20M $11.88M 1.09%
1.09%
New
28 232.18K $11.82M 1.09%
1.09%
New
29 1.21M $10.82M 0.99%
0.99%
Reduce
30 1.17M $10.78M 0.99%
0.99%
New
31 43.62K $10.66M 0.98%
0.98%
Add
32 7.32M $10.32M 0.95%
0.95%
New
33 169.64K $10.01M 0.92%
0.92%
Reduce
34 64.59K $9.39M 0.86%
0.86%
Add
35 414.43K $7.51M 0.69%
0.69%
Add
36 18.96K $7.38M 0.68%
0.68%
Add
37 13.25K $6.96M 0.64%
0.64%
New
38 130.92K $6.89M 0.63%
0.63%
Add
39 20.60K $6.14M 0.56%
0.56%
Reduce
40 13.69K $5.55M 0.51%
0.51%
New
41 392.74K $5.15M 0.47%
0.47%
New
42 23.45K $4.63M 0.43%
0.43%
New
43 358.83K $4.47M 0.41%
0.41%
Add
44 31.50K $3.25M 0.30%
0.30%
Reduce
45 325.48K $3.15M 0.29%
0.29%
Reduce
46 115.00K $2.97M 0.27%
0.27%
New
47 1.99M $2.78M 0.26%
0.26%
Add
48 167.28K $2.71M 0.25%
0.25%
Reduce
49 697.71K $2.61M 0.24%
0.24%
Hold
50 235.99K $2.32M 0.21%
0.21%
Reduce

FAQ

What did Eversept Partners, LP buy in 2025-Q2?

In its 2025-Q2 13F filing, Eversept Partners, LP reported 68 equity positions worth $1.09B in aggregate; its largest disclosed positions were NTRA ($134.54M), QQQ ($94.99M), GSK ($86.11M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.09B of long equity holdings across 68 positions as of 2025-Q2. Top-10 holdings account for 55.3% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →